Looks to develop cancer-detecting pill, self-driving cars, other innovations
By Brandon Bailey, Technology Writer
LAGUNA BEACH, Calif. (AP) --Google is working on a cancer-detecting pill in its latest effort to push the boundaries of technology.
Still in the experimental stage, the pill is packed with tiny magnetic particles, which can travel through a patient's bloodstream, search for malignant cells and report their findings to a sensor on a wearable device.
As many as 2,000 of these microscopic "nanoparticles" could fit inside a single red blood cell to provide doctors with better insights about what is happening inside their patients.
The project announced Tuesday is the latest effort to emerge from Google's X lab, which has been trying to open new technological frontiers to solve nettlesome problems and improve the quality of people's lives. The same division is also working on several other outlandish projects that have little to do with Google's main business of Internet search and advertising: Self-driving cars, a computer called Glass that looks like eyeglasses, Internet-beam balloons and contact lenses that can measure glucose in tears.
Some investors frustrated with the costs of financing X's projects ridicule them as expensive flights of fancy, but Google CEO Larry Page likens them to moonshots that could unleash future innovation and money-making opportunities.
It could be a decade before Google's nanoparticle research pays off, according to the Mountain View, California, company.
At this point, Google believes the cancer-detecting nanoparticles can be coated with antibodies that bind with specific proteins or cells associated with various maladies. The particles would remain in the blood and report back continuously on what they find over time, said Andrew Conrad, head of life sciences at Google X, while a wearable sensor could track the particles by following their magnetic fields and collecting data on their movement through the body.
The goal is to get a fuller picture of the patient's health than the snapshot that's obtained when a doctor draws a single sample of blood for tests that aren't comprehensive enough to spot the early stages of many forms of cancer.
"We want to make it simple and automatic and not invasive," Conrad added. Like Google is doing in the contact lens project, the company is here looking for ways to proactively monitor health and prevent disease, rather than wait to diagnose problems, he said.
Data from the sensor could be uploaded or stored on the Internet until it can be interpreted by a doctor, he said. That could raise questions about privacy or the security of patient data. But when asked if Google could use the information for commercial purposes, Conrad said, "We have no interest in that."
The effort to develop a better way to detect cancer was inspired by the experience of Google engineer Tom Stanis.
After getting hit by a car while bicycling, Stanis wound up in a hospital emergency room where a medical scan looking for internal bleeding alerted doctors that there was a tumor growing in his kidney.
The diagnosis probably wouldn't have been made at such an early stage if Stanis hadn't been seriously injured, prompting Google's X lab to explore better ways for doctors to keep watch for early warning signs. Stanis, who is now cancer-free, is part of the team working on X's nanoparticle technology.
Conrad described the project during an appearance at a tech industry conference organized by the Wall Street Journal. He said the team working on the nanoparticle project includes a cancer specialist and other doctors, as well as electrical and mechanical engineers and an astrophysicist who has been advising on how to track the particles through the body.
Google is looking for partners who would license the technology and bring products to market. "Our partners would take care of all that stuff. We're the inventors and creators of the technology," Conrad said.
___
AP Technology Writer Michael Liedtke in San Francisco contributed to this story.
Jennifer Kent On Why Her Feature Directing Debut, “The Babadook,” Continues To Haunt Us
"The Babadook," when it was released 10 years ago, didn't seem to portend a cultural sensation.
It was the first film by a little-known Australian filmmaker, Jennifer Kent. It had that strange name. On opening weekend, it played in two theaters.
But with time, the long shadows of "The Babadook" continued to envelop moviegoers. Its rerelease this weekend in theaters, a decade later, is less of a reminder of a sleeper 2014 indie hit than it is a chance to revisit a horror milestone that continues to cast a dark spell.
Not many small-budget, first-feature films can be fairly said to have shifted cinema but Kent's directorial debut may be one of them. It was at the nexus of that much-debated term "elevated horror." But regardless of that label, it helped kicked off a wave of challenging, filmmaker-driven genre movies like "It Follows," "Get Out" and "Hereditary."
Kent, 55, has watched all of this — and those many "Babadook" memes — unfold over the years with a mix of elation and confusion. Her film was inspired in part by the death of her father, and its horror elements likewise arise out of the suppression of emotions. A single mother (Essie Davis) is struggling with raising her young son (Noah Wiseman) years after the tragic death of her husband. A figure from a pop-up children's book begins to appear. As things grow more intense, his name is drawn out in three chilling syllables — "Bah-Bah-Doooook" — an incantation of unprocessed grief.
Kent recently spoke from her native Australia to reflect on the origins and continuing life of "The Babadook."
Q: Given that you didn't set out to in any way "change" horror, how have you regarded the unique afterlife of "The... Read More